Bioventus/Seikagaku Extend SUPARTZ FX Distribution Agreement

By Julie A. Vetalice

Bioventus extended its agreement to exclusively distribute Seikagaku's SUPARTZ FX™ in the U.S. through May 2028. The hyaluronic acid-based product treats knee osteoarthritis pain through a 5-injection regimen.

SUPARTZ FX complements Bioventus' joint fluid treatments HA GELSYN-3™ (3-injection) and DUROLANE® single-injection HA—the latter which received FDA premarket approval in late 3Q17.

Sources: Bioventus; ORTHOWORLD Inc.

Product Labels: Viscosupplement

Tags: M&A